Rapid Dose Therapeutics Third Quarter 2025 Earnings: CA$0.011 loss per share (vs CA$0.009 loss in 3Q 2024)

Rapid Dose Therapeutics (CSE:DOSE) Third Quarter 2025 Results

Key Financial Results

• Revenue: CA$501.7k (up 115% from 3Q 2024).
• Net loss: CA$1.36m (loss widened by 39% from 3Q 2024).
• CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rapid Dose Therapeutics' share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Rapid Dose Therapeutics (1 can't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.